Background {#Sec1}
==========

Renal cell carcinoma (RCC) is the third most common cancer of the urinary system and accounts for approximately 2--3% of all cancers \[[@CR1], [@CR2]\]. An estimated 65,340 new cases of kidney cancer and renal pelvic cancer, and 14,970 deaths relating to these diseases were projected for 2018 in the United States alone \[[@CR3]\]. Despite advanced diagnostic methods, one-third of clear cell RCC (ccRCC) patients are diagnosed when the cancer has already metastasized, and indicates poor prognosis. Although RCC-related mortality has decreased due to the advent of minimally invasive surgery, targeted therapy, etc., it is still a major health concern in Asia \[[@CR4], [@CR5]\]. The prognostic factors for RCC \[[@CR6]--[@CR9]\] include anatomical characteristics (tumour size, renal capsular invasion, venous invasion, etc.), histological features (tumour grade, RCC subtype, sarcomatoid features, etc.) and clinicopathological features (performance status, local symptoms, neutrophil/lymphocyte ratio, etc.). However, the predictive accuracy of the current prognostic systems associated with these markers needs to be improved. \[[@CR8]--[@CR10]\]. Therefore, the molecular mechanisms underlying the metastasis and progression of kidney cancer need to be elucidated in order to improve its prognosis.

The FBXO11 protein consists of \~ 843 amino acids with a predicted molecular weight of 94 kDa, and the encoding gene is located on chromosome 2p21. As a member of the SKP1-CUL1-F-box ubiquitin ligase complex (wherein the FBOX family members act as substrate adaptors), FBXO11 targets proteins for ubiquitination and proteosomal degradation \[[@CR11], [@CR12]\] and is therefore relevant in several diseases. For example, the FBXO11 gene is downregulated in vitiligo patients, and may be related to the loss of the pigment-producing melanocytes \[[@CR12], [@CR13]\]. Furthermore, FBXO11 also acts as a nedd8 ligase for the tumour suppressor gene *TP53* by mediating the NEDDylation of p53 protein \[[@CR13], [@CR14]\], and transcriptionally inactivating *TP53*. FBXO11 also promotes the ubiquitin-driven degradation of Snail, a transcription factor mediating the epithelial-mesenchymal transition (EMT) during cancer progression and metastasis \[[@CR15]\]. Specifically, in breast cancer, FBXO11 inhibits metastatic progression by targeting the Snail protein for degradation and blocking Snail-induced EMT \[[@CR12]\]. However, any potential clinical significance of FBOX11 in ccRCC is currently unknown, and no studies so far have investigated the correlation between FBXO11 expression and the clinico-pathological features and prognostic outcomes of ccRCC patients.

In the present study, we first examined FBXO11 expression levels in normal and malignant renal tissues using datasets available through ONCOMINE, a web-based cancer microarray database. In addition, we also analysed the in situ expression of FBXO11 in 227 ccRCC tissues (training and validation cohorts) and 40 normal kidney tissues. The association between FBXO11 expression levels and prognostic clinical outcomes was analysed using Cox regression models. Finally, a nomogram model was established using the significant prognostic factors to predict overall survival (OS).

Methods {#Sec2}
=======

Analysis of Oncomine data {#Sec3}
-------------------------

The expression pattern of FBXO11 in kidney cancer tissues was determined using the Oncomine database (<https://www.oncomine.org>). Briefly, the database was searched for the FBXO11 gene and the results were filtered by selecting kidney cancer vs. normal analysis. Box charts were used to display the data, and *P*-values for each group were calculated using Student's t-test. The specifics of normalization and statistical calculations are listed in the database program.

Patients and samples {#Sec4}
--------------------

All patients (including those in the training and validation cohorts) who were pathologically diagnosed with ccRCC at the Second Affiliated Hospital of Dalian Medical University were included in the study. Tumour tissues were collected after the first surgery, which included radical nephrectomy or nephron-sparing surgery. The clinical and pathological baseline data, including age, gender, TMN stage, tumour grade, maximum diameter of tumour, lymph metastasis, sarcomatosis and tumour necrosis were recorded. TMN staging and tumour grade was determined according to the 2004 WHO/ISUP classification. Forty normal kidney tissues were procured from surgically treated patients with renal pelvic carcinoma or ureteral urothelial carcinoma. This study was approved by the Ethics Committee of Second Affiliated Hospital of Dalian Medical University.

Immunohistochemistry (IHC) {#Sec5}
--------------------------

Tissue sections were stained by standard IHC protocols as previously described \[[@CR16]\]. Briefly, after overnight deparaffinization in dimethylbenzene and rehydration in an alcohol gradient, the sections were heated in antigen retrieval buffer at 120 °C for 5 min. After endogenous peroxidase was quenched with 3% hydrogen peroxide for 30 min, the sections were incubated at 4 °C for 24 h with primary antibodies against FBXO11 (ab110965, Abcam). The samples were then incubated with biotinylated secondary antibodies and horseradish peroxidase labelled avidin, and the colour was developed using DAB (ZSGBBIO, Beijing, China). The stromal FBXO11 expression level was analysed by two investigators who were blinded to the clinical and prognostic data. The total staining intensity was scored as: 0 (no staining), 1 (weak staining), 2 (moderate staining) and 3 (strong staining), and the percentage of positive cells was scored as: 0 (0%), 1 (1 to 50%), 2 (51 to 80%), and 3 (\> 80%). The overall FBXO11 expression was calculated by multiplying the score of the percentage of positive cells with the intensity score: 0 to 3 was defined as low expression, and \> 3 was defined high expression.

Statistical analysis {#Sec6}
--------------------

Statistical analysis was performed with SPSS 13.0 (SPSS Inc., Chicago, USA). The baseline data were compared between groups using the χ^2^ or Fisher's exact test. Correlations between clinicopathological variables and FBXO11 expression were assessed by Spearman's rank correlation test. Overall survival (OS) was defined from the onset of treatment to last follow-up (censored) or death (event), estimated by the Kaplan Meier method, and compared by the log-rank test. A multivariable Cox regression model was used to estimate the independent statistical significance of the different variables. A nomogram and calibration plot for OS based on multivariable analysis were constructed with R software (R Foundation for Statistical Computing, Vienna, Austria). The accuracy of clinical outcomes and the discriminatory ability of prognostic models were evaluated by the concordance index (C-index) and Akaike information criterion (AIC) value respectively. A *P*-value\< 0.05 was considered statistically significant.

Results {#Sec7}
=======

Higher FBXO11 mRNA levels were observed in kidney cancer tissues {#Sec8}
----------------------------------------------------------------

We analysed the FBXO11 levels in the Jones Renal microarray dataset from the Oncomine (<http://www.oncomine.org/>) dataset \[[@CR17]\]. FBXO11 expression was significantly lower in normal tissues than in cancer tissues (23 ccRCC and 11 pRCC samples) (*P* \< 0.001, *F* = 14.03, Fig. [1](#Fig1){ref-type="fig"}a). In addition, FBXO11 expression was significantly higher in the metastatic tissues than in the primary cancer tissues (*P* = 0.002, *F* = 9.474, Fig. [1](#Fig1){ref-type="fig"}b). The data of the metastatic samples are also derived from the Jones Renal microarray dataset from the Oncomine (<http://www.oncomine.org/>) dataset. In the study of the Jones data, metastatic tumours included distant and nodal metastatic ccRCC. The Beroukhim Renal microarray datasets \[[@CR18]\] showed that FBXO11 expression in normal tissue was notably lower than that in both non-hereditary and hereditary ccRCC (*P* \< 0.001, *F* = 13.61, Fig. [1](#Fig1){ref-type="fig"}c), as well as than that in VHL mutant and wild-type ccRCC (*P* \< 0.001, *F* = 13.30, Fig. [1](#Fig1){ref-type="fig"}d).Fig. 1FBXO11 expression in ONCOMINE renal tissue datasets. **a** FBXO11 expression stratified by tissue type (cancer vs. normal) in the Jones Renal microarray dataset. **b** FBXO11 expression stratified by metastasis status (metastasis vs. primary) in the Jones Renal microarray dataset. **c** FBXO11 expression stratified by hereditary characteristics (hereditary vs. non- hereditary) in the Beroukhim Renal microarray datasets. **d** FBXO11 expression stratified by VHL mutation status (mutant vs. wild-type) in the Beroukhim Renal microarray datasets

Association of FBXO11 expression with clinico-pathological factors {#Sec9}
------------------------------------------------------------------

To determine the clinical relevance of FBXO11 expression in ccRCC, we evaluated the in situ levels in tumour tissues resected from patients in the two cohorts. (Fig. [2](#Fig2){ref-type="fig"}). Based on staining intensity, we divided the 227 ccRCC patients into the low-FBXO11 (*n* = 97) and high-FBXO11 (*n* = 130) groups. Positive FBXO11 expression was observed in 57.3% (130/227) of the ccRCC, tissues but only 17.5% (7/40) of the normal kidney tissues. A total of 57.3% (86 of 150) in the training cohort and 57.1% (44 of 77) in the validation cohort of tumour tissues weas scored as having high FBXO11 staining density. The correlations between FBXO11 expression and major clinico-pathological features, including age, gender, tumour size, Fuhrman grade, T stage, sarcomatoid status, lymph node status, distant metastasis and types of surgery are summarized in Table [1](#Tab1){ref-type="table"}. Moreover, FBXO11 expression was significantly associated with Fuhrman grade (*p* = 0.003), UISS score (*p* = 0.021) and age (*p* = 0.048) in the training cohort was significantly related to UISS score (*p* = 0.012) in the validation cohort.Fig. 2Representative immunohistochemical staining of FBXO11 expression in RCC specimens at 200 magnification**. a** No expression of FBXO11 in normal kidney tissue (0% staining) as a contrast. **b** Low expression of FBXO11 in RCC tissue with Fuhrman 1 (15% staining). **c** High expression of FBXO11 in RCC tissue with Fuhrman 2 (50% staining). **d** High expression of FBXO11 in RCC tissue with Fuhrman 3 (80% staining). **e** High expression of FBXO11 in RCC tissue with Fuhrman 4 (100% staining). A high expression level of FBXO11 appears as brown yellow or brown particlesTable 1Distribution of characteristics of two independent patient cohorts with RCC by FBXO11 expressionPatient characteristicsTraining cohort (150 patients)Total*P* ValueValidation cohort (77patients)Total*P* ValueLowHighLowHighGender0.2270.644 Male4163104172542 Female232346161935Age, years**0.048**0.099 \<57383775191736 ≥57264975142741Tumor size0.7380.394 ≤4 cm303565151429 4 cm--7 cm243559132437 ≥7 cm1016265611Fuhrman grade**0.003**0.111 I-II473986221941 III14375181624 IV310133912Pathologic stage0.0650.291 T15866124282957 T2513182810 T3178257 T4000123Lymph node status0.7640.423 No6284146313970 N1- Nx254257Distant metastasis0.1310.894 Absent6483147314172 Present033235Sarcomatoid0.8460.894 Absent5980139314172 Present5611235Type of surgery0.3950.836 Radical nephrectomy4262104212950 Partial nephrectomy.222446121527UISS score**0.0210.012** 15252104262046 211294072330 3156011SSIGN score0.2050.070 0--35870128272653 4--76142031316 ≥8358358Bold values are considered statistically significant (*p* \< 0.05)

High FBXO11 expression corresponded to poor prognosis in ccRCC {#Sec10}
--------------------------------------------------------------

The Kaplan Meier survival curve showed that higher FBXO11 levels, T stage, UISS score and SSIGN score were associated with poor OS not only in the training cohort, but also in the validation cohort (Fig. [3](#Fig3){ref-type="fig"}a-d and Fig. [4](#Fig4){ref-type="fig"}a-d). After univariate and multivariate analysis under the Cox proportional hazard model, higher FBXO11 expression levels were found to be independent prognostic indicators in not only the training cohort (HR =2.381; 95% CI = 1.089--5.205; *P* = 0.030) but also the validation cohort (HR =4.075; 95% CI = 1.280--12.971; *P* = 0.017). Meanwhile, a higher UISS score also predicted poor OS of ccRCC patients in both two cohort groups (HR = 2.766; 95% CI = 1.139--6.713; *P* = 0.025 and HR =2.781; 95% CI = 1.059--7.300; *P* = 0.038, respectively) (Table [2](#Tab2){ref-type="table"}). Taken together, these data indicate that FBXO11 upregulation was associated with poor ccRCC patient prognosis, and predicted worse OS in ccRCC patients after radical nephrectomy.Fig. 3Generated survival curves for training cohort patients generated using the Kaplan-Meier method and log-rank tests. **a** Overall survival curves for low FBXO11 expression (green line) and high FBXO11 expression (blue line), indicating that a high level of FBXO11 protein was significantly associated with worse survival in the IHC cohort. **b** Overall survival curves for T1 stage (blue line), T2 stage (green line, 2), and T3 stage (light yellow line), suggesting that RCC patients with T3 stage disease had worse survival than individuals with T1 stage or T2 stage disease. **c** Overall survival curves for UISS score 1 (blue line), UISS score 2 (green line) and UISS score 3 (light yellow line), illustrating that RCC patients with a UISS score of 1 had better survival than individuals with a UISS score 2 or 3. **d** Overall survival curves for SSIGN score 0--3 (blue line), SSIGN score 4--7 (green line) and SSIGN score ≥ 8 (light yellow line), demonstrating that RCC patients with a lower SSIGN score had better overall survival than individuals with a high SSIGN scoreFig. 4Generated survival curves for validation cohort patients using the Kaplan-Meier method and log-rank tests. **a** Overall survival curves for low FBXO11 expression (green line) and high FBXO11 expression (blue line), indicating high level of FBXO11 protein was significantly associated with worse survival in the IHC cohort. **b** Overall survival curves for T1 stage (blue line), T2 stage (green line, 2), and T3 stage (light yellow line), suggesting that RCC patients with T3 stage had worse survival than individuals with T1 stage or T2 stage. **c** Overall survival curves for UISS score 1 (blue line), UISS score 2 (green line) and UISS score 3 (light yellow line), illustrating that RCC patients with a UISS score of 1 had better survival than individuals with a UISS score of 2 or 3. **d** Overall survival curves for SSIGN score 0--3 (blue line), SSIGN score 4--7 (green line) and SSIGN score ≥ 8 (light yellow line), demonstrating that RCC patients with a lower SSIGN score had better survival than individuals with a high SSIGN scoreTable 2Univariate and multivariate analyses for overall survival (OS) including pre-operatively known parameters as well as FBXO11 in 222 RCC patients treated with surgeryOverall SurvivalTraining cohort (150 patients)Validation cohort (77 patients)Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysisHR*p* ValueHR*p* ValueHR*p* ValueHR*p* ValueGender0.500 (0.219--1.142)0.100----0.956 (0.428--2.135)0.913----Age1.664 (0.851--3.253)0.136----1.554 (0.680--3.554)0.296----Tumor size1.606 (1.037--2.489)**0.034**1.276 (0.771--2.113)0.3431.461 (0.811--2.635)**0.207**1.267 (0.665--2.414)0.471FBXO112.817 (1.323--5.997)**0.007**2.381 (1.089--5.205)**0.030**5.740 (1.951--16.891)**0.002**4.075 (1.280--12.971)**0.017**Fuhrman grade1.639 (1.045--2.568)**0.031**0.913 (0.533--1.563)0.7401.964 (1.206--3.198)**0.007**1.178 (0.708--1.960)0.529Pathologic stage1.730 (1.089--2.747)**0.020**0.570 (0.243--1.338)0.1971.470 (0.971--2.226)0.069Lymph node status3.013 (0.723--12.557)0.1302.571 (0.873--7.577)0.087Distant metastasis1.732 (0.237--12.644)0.588----3.246 (0.961--10.961)0.058----Sarcomatoid1.776 (0.628--5.028)0.279----1.292 (0.303--5.499)0.729----Type of surgery1.366 (0.692--2.696)0.3691.351 (0.600--3.042)0.468UISS score system2.316 (1.489--3.601)**0.001**2.766 (1.139--6.713)**0.025**5.821 (2.604--13.015)**0.001**2.781 (1.059--7.300)**0.038**SSIGN score system2.174 (1.240--3.812)**0.007**1.240 (0.503--3.061)0.6402.318 (1.404--3.826)**0.001**1.565 (0.774--3.163)0.212Bold values are considered statistically significant (*p* \< 0.05)

Nomogram of prognostic prediction based on FBXO11 expression in primary lesions {#Sec11}
-------------------------------------------------------------------------------

To predict the 1-, 3- and 5-year OS rates of individual ccRCC patients, a novel nomogram model was established using the four significant prognostic factors in conjunction with age, gender, Fuhrman grade, tumour size, type of surgery, sarcomatoid, lymph node status and distant metastasis (Fig. [5](#Fig5){ref-type="fig"}). The calibration plots of the nomogram are shown for 1-, 3- and 5-year OS prediction (Fig. [6](#Fig6){ref-type="fig"}), of which the predictive probability of 3-year OS was very close to the actual 3-year OS. ROC curves of the 1-, 3- and 5-year nomograms are shown in Fig. [7](#Fig7){ref-type="fig"}a-c, with respective AUC values of 0.930, 0.792 and 0.757(Fig. [7](#Fig7){ref-type="fig"}).Fig. 5Nomogram model for the probability of 1-, 3- and 5- years overall survival (OS) predictions. The nomogram was used by summing the points based on the point designations corresponding to related factors including tumour-specific factors (size, SSIGN score, UISS score, differentiation, sarcomatoid, T stage), patient-specific factors (age, gender, type of surgery, lymph node status and distant metastasis) and FBXO11 expressionFig. 6Calibration plots for predicting OS after nephrectomy . **a** Calibration plots for predicting OS at 1 year. **b** Calibration plots for predicting OS at 3 years. **c** Calibration plots for predicting OS at 5 years. The blue dotted line indicates the ideal nomogram; circles indicate the apparent predictive accuracy; blue X indicates the bootstrap-corrected estimates; vertical bars indicates the 95% CIsFig. 7ROC curves of the 1-, 3- and 5-year nomograms of the training cohort after nephrectomy. **a** ROC curves of 1-year nomograms. **b** ROC curves of 3-year nomograms. **c** ROC curves of 5-year nomograms. The red lines represent nomogram-predicted overall survival rates, whereas the black lines represent AJCC TNM stage-predicted overall survival rates

Extension of postoperative prognostic systems with FBXO11 expression {#Sec12}
--------------------------------------------------------------------

To establish a more sensitive model for predicting outcomes of patients with ccRCC, we combined FBXO11 expression with the UISS or SSIGN score and assessed their accuracy of survival. Incorporation of FBXO11 increased the predictive value of these three models, namely, when assessing OS: 0.703 versus 0.674 for the UISS score cohort, and 0.676 versus 0.598 for the SSIGN score cohort (Table [3](#Tab3){ref-type="table"}). The elevated tendency of the C-index and the decreased trend of AIC suggest a better predictive accuracy. These results indicate that a combination of FBXO11 and conventional prognostic models could generate better predictive systems for ccRCC patient outcomes.Table 3Comparison of the prognostic accuracies of models for overall survivalModelsTraining cohort (150 patients)Validation cohort (77 patients)C-indexAICC-indexAICFBXO110.628343.010.692185.42UISS0.674339.380.728179.34UISS + FBOX110.703336.580.780175.13SSIGN0.598345.660.665190.02SSIGN + FBOX110.676340.920.757178.22

Discussion {#Sec13}
==========

Metastatic RCC presents the dual challenges of high mortality rates and significant management costs, thus highlighting the need to identify novel prognostic markers or therapeutic targets. Using the microarray datasets in ONCOMINE, we found that FBXO11 expression was lower in normal kidney tissues than in both ccRCC and pRCC, tissues and in primary cancers than in metastatic cancers. In addition, positive in situ FBXO11 expression was observed in 57.3% of the RCC tissues as opposed to 17.5% of the normal tissues. Furthermore, multivariate analysis showed that higher FBXO11 levels and larger tumour size were independent prognostic indicators of worse OS in patients. Taken together, these data suggest that high FBXO11 expression is associated with the degree of malignancy and poor patient prognosis for ccRCC. Based on its established oncogenic role in various cancer models, FBXO11 likely contributes to ccRCC progression.

The FBXO11 gene was first described as the vitiligo gene (VIT1) located on chromosome 2p21 and downregulated in vitiligo, a skin disorder characterized by the loss of melanocytes \[[@CR19]\]. FBXO11 was identified as the substrate binding receptor in the Cullin RING E3 ubiquitin ligase 1 complex (also known as the SCF complex or the CRL1FBXO11 ubiquitin ligase) \[[@CR20]\], a master regulator of cell cycle progression and genome stability \[[@CR21]\]. FBXO11 stabilizes the CRL4Cdt2 substrates p21 and Set8 ubiquitylation and degradation of via Cdt2 (Cdc10-dependent transcript 2, also known as DTL/RAMP), and upregulates Set8 to promote Pr-Set7/Set8-mediated cellular migration \[[@CR22]\]. Set8 accumulation in TGFβ-treated cells showed a decrease in Smad2 phosphorylation and N-cadherin induction \[[@CR22]\]. This indicated that FBXO11-mediated Cdt2 degradation restrains the cellular response to TGFβ. Rossi et al. hypothesized that FBXO11-dependent degradation of Cdt2 controls the timing of cell cycle exit and differentiation \[[@CR23]\]. In addition, FBXO11 mediates the degradation of the EMT transcription factor Snail in breast cancer cells. FBXO11 can not only cause direct ubiquitination and degradation of their target proteins, but also indirectly inhibit their function. For example, it promotes Nedd8 conjugation to p53, which inhibits the latter's function \[[@CR24]\].

Correlation analysis showed that tumour differentiation status was positively correlated with FBXO11 expression, indicating a higher probability of FBXO11 overexpression in poorly or moderately differentiated tumours than in highly differentiated tumours \[[@CR25]\]. FBXO11 can regulate tumour formation or progression via several processes, such as growth suppression, EMT and angiogenesis. FBXO11 gene silencing led to the development of diffuse large B-cell lymphoma (DLBCL) by targeting the degradation of Bcl-6 \[[@CR26]\], while FBXO11 inactivation resulted in abnormal germinal-centre formation. This activity is related to FBXO11-mediated degradation of phosphorylated Bcl-6 during BCR engagement \[[@CR27]\]. While FBXO11 promotes proliferation, migration and invasion of gastric cancer cells via PI3K/AKT pathway-mediated EMT \[[@CR28]\], it acts as a tumour suppressor in lung and breast cancer by degrading SNAIL, via promotion of serine-11 phosphorylation by protein kinase D1 (PKD1), and inhibiting SNAIL-induced EMT \[[@CR15]\]. Finally, the ubiquitin ligase activity of FBXO11 destabilizes and inhibits de novo synthesis of HIF-1a, thereby promoting the glioblastoma cell response to hypoxia and inhibiting angiogenesis \[[@CR29], [@CR30]\].

Mutations or deletions in FBXO11 have been observed in various neoplastic and non-neoplastic conditions. For example, the Jeff mouse model of chronic otitis media harbours a FBXO11 mutation \[[@CR31]\], which interferes with TGF-βsignalling \[[@CR32], [@CR33]\]. FBXO11 is also a target of miR-21 \[[@CR30]\] and miR-26a, and the latter inhibits hepatocellular carcinoma (HCC) cell proliferation and metastasis by suppressing FBXO11 \[[@CR34]\]. It is a direct functional target of miR-621 in breast cancer, and high miR-621 levels enhance the sensitivity of breast cancer cells to paclitaxel and carboplatin by suppressing FBXO11 and enhancing p53 activity \[[@CR14]\]. Taken together, these findings support the notion that FBXO11 has a strong oncogenic role in HCC and breast cancer.

We established a prognostic nomogram model to predict the 1-, 3- and 5-year OS rates of individual ccRCC patients on the basis of FBXO11 expression, T stage, UISS score and SSIGN score combined with age, gender, Fuhrman grade, tumour size, type of surgery, sarcomatoid status, lymph node status and distant metastasis. Calibration plots of the nomograms indicated that the predicted 3-year OS closely corresponded to the actual 3-year OS, indicating high accuracy, specificity and simplicity of the model, which makes it feasible for regular clinical use \[[@CR35]--[@CR38]\].

There are several limitations of this study. First, the Kaplan--Meier and Cox regression analyses were conducted on a limited cohort size \[[@CR39]\]. Second, we did not include all clinico-pathological parameters, such as postoperative adjuvant therapy, because they were unavailable. All of the limitations could have introduced potential selection bias.

Conclusion {#Sec14}
==========

FBXO11 expression is an independent predictor of poor OS in ccRCC patients, indicating its potential as a prognostic factor and therapeutic target. More large-scale multicentre studies on ccRCC patients with long-term follow-up are needed to validate our findings. In addition, the exact mechanistic basis and signalling pathways underlying FBXO11 activity in urinary cancer have to be elucidated.
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